Pulnovo Medical Raises Funds to Support Global Trials of Pulmonary Artery Denervation Device

August 3, 2021—Pulnovo Medical, a China-based medical device company based in Nanjing, China, that specializes in the treatment of pulmonary artery hypertension, announced the completion of funding round that will be used for the company's full pipeline product layout and global multicenter clinical trials of its pulmonary artery denervation (PADN) device. The company stated that it raised millions of dollars through OrbiMed Healthcare Fund Management, Cenova Capital, Lilly Asia Ventures (LAV), and GaoRong Capital.

On June 28, the company announced the completion of patient enrollment in the PADN-CFDA (Pulmonary Artery Denervation-China FDA) randomized controlled trial of the PADN device to treat pulmonary artery hypertension. In January 2021, Pulnovo Medical’s radiofrequency ablation product was granted United States FDA Breakthrough Device designation.

According to Pulnovo Medical, the energy source used in its procedure is optimal, stable, and suitable for PADN therapy. The shape of Pulnovo's device is in line with the inner wall of the pulmonary artery, providing improved safety and efficiency of radiofrequency ablation, while significantly reducing the procedure time.

"The road of global medical innovation has never been an easy journey," commented Cynthia Chen, Pulnovo Medical's Executive President, in the company's press release. "We have carefully selected professional healthcare investors as our partners. For the past few years, we are grateful to have Chiron-Ventures standing with us to set a strong foundation for the future. Today, we are honored for the recognition and support from OrbiMed, Cenova Capital, Lilly Asia Ventures (LAV), and GaoRong Capital. We are confident and excited for the next chapter of Pulnovo Medical."